Use of adjuvant therapy remains controversial.
No president biomarkers have been able to accurately predict which patients with stage II colorectal cancer would gain benefit from adjuvant therapy.
No solid evidence showing that chemotherapy given after surgery for stage II CRC improve survival and benefits of adjuvant chemotherapy remain a matter of debate.
SEER data and Medicare database review of nearly 25,000 patients concluded there was no difference in five years survival between those who received postoperative chemotherapy and those who did not.
Oncotype DX Colon Cancer test, and ColoPrint are not predictive of adjuvant treatment benefits for patients with stage II disease.